Nomura Initiates Tetraphase Pharmaceuticals With Buy

Analysts at Nomura initiated coverage on Tetraphase Pharmaceuticals, Inc. TTPH with a Buy rating. The target price for Tetraphase Pharmaceuticals is set to $54. Tetraphase Pharmaceuticals shares have gained 233.05% over the past 52 weeks, while the S&P 500 index has surged 13.49% in the same period. Tetraphase Pharmaceuticals' shares fell 4.30% to close at $39.20 on Friday.